<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighteen patients in a high-blast group of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were treated with low-dose SM-108 (4-carbamoylimidazolium 5-olate) </plain></SENT>
<SENT sid="1" pm="."><plain>Seven of the 18 patients (38.9%) achieved a partial response, and 4 (22.2%) achieved complete response </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment was associated with significant, but transient myelotoxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Changes in CFU-GEMM clonal growth were examined in bone marrow from patients during the treatment </plain></SENT>
</text></document>